Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Pharmacogenomic Factors Such as the Expression of Imatinib Transporters (OCT-1, ABCB-1 and ABCG-2) at Diagnosis, OCT-1 SNPs, and Steady-State Imatinib and Desmethyl-Imatinib Trough Plasma Levels in De Novo Chronic Phase Chronic Myelogenous Leukemia, May Influence Disease Response to Imatinib

Hélène Labussière, MD, Sandrine Hayette, PhD, Kaddour Chabane, BSc, Marie-Claude Gagnieu, PharmD, Quoc-Hung Lê, MD, PhD, Isabelle Tigaud, MD, Joëlle Bernard, BSc, Fiorenza Barraco, MD, Jean-Pierre Magaud, MD, PhD, Mauricette Michallet, MD, PhD, Franck E Nicolini, MD, PhD

Blood (2008) 112 (11): 2643.

https://doi.org/10.1182/blood.V112.11.2643.2643

Published: 2008

Journal Articles

Impact of Chimerism and Other Transplant Variables on Allogeneic Transplant Outcome after Reduced Intensity Conditioning (RIC) Regimens.

Veronica Ortiz Corbella, MD, Quoc-Hung Lê, MD, Franck E. Nicolini, MD, PhD, Anne Thiébaut, MD, Xavier Thomas, MD, PhD, Youcef Chelgoum, MD, Sophie Ducastelle, MD, Isabelle Mollet, PhD, Valérie Dubois, MD, Mauricette Michallet, MD, PhD

Blood (2006) 108 (11): 5258.

https://doi.org/10.1182/blood.V108.11.5258.5258

Published: 2006

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Cures CLL: A Retrospective Analysis from the SFGM-TC Registry.

Mauricette Michallet, MD, PhD, Quoc-Hung Lê, MD, Jean-Paul Vernant, MD, PhD, Franck E. Nicolini, MD, PhD, Jean-Luc Harousseau, MD, PhD, Philippe Colombat, MD, PhD, Eric Deconninck, MD, PhD, Bruno Cazin, MD, Didier Blaise, MD, PhD

Blood (2006) 108 (11): 2991.

https://doi.org/10.1182/blood.V108.11.2991.2991

Published: 2006

Journal Articles

Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.

Franck E. Nicolini, MD, PhD, Emmanuel Bachy, MD, Sélim Corm, MD, Quoc-Hung Lê, MD, Sandrine Hayette, PhD, Dominique Bories, MD, PhD, Michel Tulliez, MD, Nathalie Sorel, MD, Francois Guilhot, MD, Laurence Legros, MD, François-Xavier Mahon, MD, PhD, Frédéric Maloisel, MD, Jean-Jacques Kiladjian, MD, PhD, Catherine Roche-Lestienne, PhD, Claude Preudhomme, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2006) 108 (11): 2190.

https://doi.org/10.1182/blood.V108.11.2190.2190

Published: 2006

Journal Articles

P-Loop an T315I BCR-ABL Mutations in Chronic Myelogenous Leukemia (CML) Patients Are of Poor Prognosis, but the Y253H + E255K P-Loop Mutations Are of Even More Severe Prognosis in Chronic Phase. On the Behalf of the French Intergroup of CML (Fi-LMC Group).

Franck E. Nicolini, MD, PhD, Sélim Corm, MD, Quoc-Hung Lê, MD, Sandrine Hayette, PhD, Nathalie Sorel, PhD, Dominique Bories, MD, PhD, Stéphane Giraudier, MD, PhD, Michel Tulliez, MD, Philippe Rousselot, MD, Jean-Michel Cayuela, MD, François-Xavier Mahon, MD, PhD, Pascale Cony-Makhoul, MD, Jean-Jacques Kiladjian, MD, Olivier Tournilhac, MD, François Guilhot, MD, Catherine Roche-Lestienne, PhD, Claude Preudhomme, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2005) 106 (11): 3284.

https://doi.org/10.1182/blood.V106.11.3284.3284

Published: 2005

NARROW

Pharmacogenomic Factors Such as the Expression of Imatinib Transporters (OCT-1, ABCB-1 and ABCG-2) at Diagnosis, OCT-1 SNPs, and Steady-State Imatinib and Desmethyl-Imatinib Trough Plasma Levels in De Novo Chronic Phase Chronic Myelogenous Leukemia, May Influence Disease Response to Imatinib

Impact of Chimerism and Other Transplant Variables on Allogeneic Transplant Outcome after Reduced Intensity Conditioning (RIC) Regimens.

Allogeneic Hematopoietic Stem Cell Transplantation Cures CLL: A Retrospective Analysis from the SFGM-TC Registry.

Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.

P-Loop an T315I BCR-ABL Mutations in Chronic Myelogenous Leukemia (CML) Patients Are of Poor Prognosis, but the Y253H + E255K P-Loop Mutations Are of Even More Severe Prognosis in Chronic Phase. On the Behalf of the French Intergroup of CML (Fi-LMC Group).

Email alerts

ASH Publications

American Society of Hematology

Pharmacogenomic Factors Such as the Expression of Imatinib Transporters (OCT-1, ABCB-1 and ABCG-2) at Diagnosis, OCT-1 SNPs, and Steady-State Imatinib and Desmethyl-Imatinib Trough Plasma Levels in De Novo Chronic Phase Chronic Myelogenous Leukemia, May Influence Disease Response to Imatinib

Impact of Chimerism and Other Transplant Variables on Allogeneic Transplant Outcome after Reduced Intensity Conditioning (RIC) Regimens.

Allogeneic Hematopoietic Stem Cell Transplantation Cures CLL: A Retrospective Analysis from the SFGM-TC Registry.

Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.

P-Loop an T315I BCR-ABL Mutations in Chronic Myelogenous Leukemia (CML) Patients Are of Poor Prognosis, but the Y253H + E255K P-Loop Mutations Are of Even More Severe Prognosis in Chronic Phase. On the Behalf of the French Intergroup of CML (Fi-LMC Group).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only